株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ヒトマイクロバイオームベースの薬剤・診断技術の世界市場

Human Microbiome-based Drugs and Diagnostics: Global Markets

発行 BCC Research 商品コード 507469
出版日 ページ情報 英文 124 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.81円で換算しております。
Back to Top
ヒトマイクロバイオームベースの薬剤・診断技術の世界市場 Human Microbiome-based Drugs and Diagnostics: Global Markets
出版日: 2017年05月25日 ページ情報: 英文 124 Pages
概要

世界のヒトマイクロバイオームベースの薬剤・診断技術の市場は2024年には99億ドルに近い規模に成長すると予測されています。

当レポートでは、世界のヒトマイクロバイオームベースの薬剤・診断技術の市場を調査し、マイクロバイオームの概要、薬剤の開発状況と現在の課題、診断技術の概要および用途、疾患区分別の動向と市場規模の推移と予測、特許・投資・企業間提携などの動向、主要企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 サマリー・ハイライト

第3章 マイクロバイオーム:概要

  • マイクロバイオームの概要
    • 科学的背景
    • 健康・疾患におけるヒトマイクロバイオーム
    • マイクロバイオーム研究の進歩
  • ヒトマイクロバイオーム薬剤・診断の対象
  • マイクロバイオーム薬剤:製品開発戦略
  • マイクロバイオーム薬剤開発:現在の課題

第4章 ヒトマイクロバイオーム薬剤の市場

  • 肥満症
  • 2型糖尿病
  • 潰瘍性大腸炎・クローン病
  • クロストリジウムディフィシル感染症
  • 乳糖不耐症
  • 虫歯
  • 再発性細菌性腔炎・尿路感染症
  • 皮膚疾患
  • 高シュウ酸尿症
  • 尿素サイクル異常症
  • セリアック病
  • フェニルケトン尿症
  • 非アルコール性脂肪性肝炎 (NASH)
  • 肝性脳症
    • 背景
    • マイクロバイオームの重要性
    • 開発中の薬剤:レビュー
    • マイクロバイオーム治療薬の市場

第5章 ヒトマイクロバイオーム診断の市場

  • ヒトマイクロバイオーム診断
    • マイクロバイオーム診断:概要
    • マイクロバイオーム診断:技術
    • マイクロバイオーム診断:用途
    • マイクロバイオーム診断:業界における協力・提携
    • マイクロバイオーム診断市場
      • 潰瘍性大腸炎・クローン病
      • 女性の疾患
      • 虫歯

第6章 マイクロバイオーム関連IP・投資・提携

  • マイクロバイオーム関連IP・投資・提携
  • IP
    • 概要
    • 特許区分
    • 特許:疾患区分別
  • 投資・提携
    • 概要
    • 公共投資
    • 民間投資
    • コラボレーション
    • 公共データベース:概要

第7章 企業プロファイル

図表

目次
Product Code: BIO151A

Report Highlights

The global market for human microbiome-based drugs and diagnostics should reach a market size of nearly $9.9 billion by 2024.

Report Includes:

  • An overview of the global markets for human microbiome-based drugs and diagnostics.
  • Analyses of global market trends, with estimates from 2017, and projections of compound annual growth rates (CAGRs) through 2024.
  • Coverage of areas and applications where these technologies are applicable, such as cancer, diabetes, allergic disorders, irritable bowel disorders, celiac disease, and other G.I. disorders.
  • An in-depth look at macro-level trends affecting this sector.
  • Market intelligence on the technologies and platforms currently being deployed to develop these drugs and diagnostics.
  • Specific emphasis on the products in development for various diseases, including the specific forecasts for these products by disease and geography.
  • A look at the current level of investments in the sector, intellectual property development, and future of this sector.

Report Scope

The scope of the study includes the major microbiome-based drugs and diagnostics that are likely to be commercialized within the next eight years. Each product within each market is analyzed to determine its market status, market potential during the time period of 2018 to 2024. Microbiome intellectual property, investments and collaborations are discussed.

Influencing factors, industry structure, challenges facing the industry and patent status are discussed. BCC Research examines companies in the industry, corporate alliances and assay consumption by indication. We profile 25+ companies participating in this rapidly developing and evolving sector.

Analyst Credentials

The author, Megashwin Mehta, is a seasoned professional with more than 10 years of experience in working across a variety of sectors, including the life sciences industry. The author has held positions in market development, sales, marketing and analysis in the healthcare sector, and holds a Bachelor of Science in Pharmaceutical Sciences.

Table of Contents

Chapter 1 - Introduction

  • Introduction
    • Study Goals and Objectives
    • Reasons for Doing This Study
    • Intended Audience
    • Scope of Report
    • Information Sources
    • Methodology
    • Geographic Breakdown
    • Analyst's Credentials
    • Related BCC Research Reports

Chapter 2 - Summary and Highlights

  • Summary and Highlights

Chapter 3 - Microbiome Overview

  • Microbiome Overview
    • Scientific Background
    • Human Microbiome in Health and Disease
    • Advances in Microbiome Research
      • Human Microbiome Project
      • MetaHIT Consortium
      • Public Sector Initiatives in Microbiome Research
    • Focus Areas for Microbiome-Based Drugs and Diagnostics
    • Microbiome-Based Drugs: Product Development Strategies
    • Current Challenges in Microbiome Drug Development

Chapter 4 - Human Microbiome-Based Drugs Market

  • Cancer
    • Background
    • Microbiome and Cancer
    • Microbiome-based Drugs for Cancer: Review of Drugs in Development
    • Market for Microbiome-based Drugs for Cancer
  • Obesity
    • Background
    • Microbiome and Obesity
    • Microbiome-based Drugs for Obesity: Review of Drugs in Development
    • Market for Microbiome-based Drugs for Obesity
  • Type 2 Diabetes
    • Background
    • Microbiome and Type 2 Diabetes
    • Microbiome-based Drugs in Type 2 Diabetes: Review of Drugs in Development
    • Market for Microbiome-based Drugs for Type 2 Diabetes
  • Ulcerative Colitis and Crohn's Disease
  • Background
    • Microbiome and Ulcerative Colitis/Crohn's Disease
    • Microbiome-based Drugs for Ulcerative Colitis and Crohn's Disease: Review of Drugs in Development
    • Market for Microbiome-Based Products for Ulcerative Colitis and Crohn's Disease
  • Clostridium Difficle Infection
    • Background
    • Microbiome and Clostridium Difficle Infection
    • Microbiome-based Drugs for Clostridium Difficle Infection: Review of Drugs in Development
    • Market for Microbiome-based Drugs for Clostridium Difficle Infection
  • Lactose Intolerance
    • Background
    • Microbiome and Lactose Intolerance
    • Microbiome-based Drugs for Lactose Intolerance: Review of Drugs in Development
    • Market for Microbiome-based Product for Lactose Intolerance
  • Dental caries
    • Background
    • Microbiome and Dental Caries
    • Microbiome-based Drugs for Dental Caries Review of Drugs in Development
    • Market for Microbiome-based Products for Dental Caries
  • Recurrent Bacterial Vaginosis and Urinary Tract Infection
    • Background
    • Microbiome and Recurrent Bacterial Vaginosis and Urinary Tract Infection
    • Microbiome-based Drugs for Recurrent Bacterial Vaginosis and Urinary Tract Infection: Drugs in Development
    • Market for Microbiome-based Products for Recurrent Bacterial Vaginosis and UTI
  • Skin Diseases
    • Background
    • Microbiome and Skin Diseases
    • Microbiome-based Drugs for Skin Diseases: Review of Drugs in Development
    • Market for Microbiome-based Drugs for Skin Diseases
  • Hyperoxaluria
    • Background
    • Microbiome and Hyperoxaluria
    • Microbiome-based Drugs for Hyperoxaluria: Review of Drugs in Development
    • Market for Microbiome-based Products for Hyperoxaluria
  • Urea Cycle Disorder
    • Background
    • Microbiome and Urea Cycle Disorder
    • Microbiome-based Drugs for Urea Cycle Disorder: Review of Drugs in Development
    • Market for Microbiome-Based Drugs for Urea Cycle Disorder
  • Celiac Disease
    • Background
    • Microbiome and Celiac Disease
    • Microbiome-Based Drugs for Celiac Disease: Review of Drugs in Development
    • Market for Microbiome-based Products for Celiac Disease
  • Phenylketonuria
    • Background
    • Microbiome and Phenylketonuria
    • Microbiome-based Drugs for Phenylketonuria: Review of Drugs in Development
    • Market for Microbiome-based Products for Phenylketonuria
  • Non-alcoholic Steatohepatitis (NASH)
    • Background
    • Microbiome and Non-alcoholic Steatohepatitis
    • Microbiome-based Drugs for Non-alcoholic Steatohepatitis: Review of Drugs in Development
    • Market for Microbiome-based Products for Non-alcoholic Steatohepatitis
    • Microbiome-based Products for Hepatic Encephalopathy
    • Microbiome and Hepatic Encephalopathy
    • Microbiome-based Drugs for Hepatic Encephalopathy: Review of Drugs in Development
    • Market for Microbiome-based Drugs for Hepatic Encephalopathy

Chapter 5 - Human Microbiome-based Diagnostics Market

  • Human Microbiome-based Diagnostics Market
    • Microbiome Diagnostics: Overview
    • Microbiome Diagnostics: Technologies
    • Microbiome Diagnostics: Applications
    • Microbiome Diagnostics: Industry Collaborations
    • Market for Microbiome Diagnostics
      • Microbiome-based Diagnostics for Ulcerative Colitis and Crohn's Disease
      • Microbiome-based Diagnostics for Cancer
      • Microbiome Diagnostics for Women's Health
      • Microbiome Diagnostics for Dental caries

Chapter 6 - Microbiome Intellectual Property, Investments and Collaborations

  • Microbiome Intellectual Property, Investments and Collaborations
    • Intellectual Property
      • Overview
      • Microbiome Patent Segments
      • Patents by Disease Area
    • Investments and Collaborations
      • Investments: Overview
      • Public Sector Investments
      • Private Sector Investments
      • Collaborations: overview
      • Microbiome Public Databases Overview

Chapter 7 - Company Profiles

  • Company Profiles

Lists of Tables and Figures

About BCC Research

  • About BCC Research
  • BCC Library Access
  • BCC Custom Research

List of Tables

  • TABLE 1: Summary Table: Global Market for Human Microbiome Based Drugs by Disease Indication, through 2024 ($ Millions)
  • TABLE 2: Focus Disease Areas for Microbiome Research
  • TABLE 3: Microbiome Drug Development Approaches
  • TABLE 4: U.S. Prevalence of Cancer, through 2024 (Thousands)
  • TABLE 5: Microbiota Associated with Cancers
  • TABLE 6: Microbiome-based Drugs in Development for Cancer
  • TABLE 7: U.S. Market Shares of Microbiome-based Drugs for Cancer, by Company, 2018-2024 (%)
  • TABLE 8: U.S. Patient Volumes for Microbiome-based Drugs for Cancer, by Company, through 2024 (Thousands)
  • TABLE 9: U.S. Market for Microbiome-based Drugs for Cancer, by Company, through 2024 (Thousands)
  • TABLE 10: Rest of the World Market for Microbiome-based Drugs for Cancer, by Country/Region, through 2024 (Thousands)
  • TABLE 11: U.S. Prevalence of Obesity, through 2024 (Thousands)
  • TABLE 12: Microbiota Associated with Obesity
  • TABLE 13: Microbiome-based Drugs in Development for Obesity
  • TABLE 14: U.S. Market Shares of Microbiome-based Drugs for Obesity, by Company, 2018-2024 (%)
  • TABLE 15: U.S. Patient Volumes for Microbiome-based Drugs for Obesity, by Company, through2024 (Thousands)
  • TABLE 16: U.S. Market for Microbiome-based Drugs for Obesity, by Company, through 2024 ($ Millions)
  • TABLE 17: U.S. Prevalence of Type 2 Diabetes, through 2024 (Thousands)
  • TABLE 18: Microbiota Associated with Type 2 Diabetes
  • TABLE 19: Microbiome-based Drugs in Development for Type 2 Diabetes
  • TABLE 20: U.S. Market Shares of Microbiome-based Drugs for Type 2 Diabetes, by Company, 2018-2024 (%)
  • TABLE 21: U.S. Patient Volumes for Microbiome-based Drugs for Type 2 Diabetes, by Company, through 2024 (Thousands)
  • TABLE 22: U.S. Market for Microbiome-based Drugs for Type 2 Diabetes, by Company, through 2024 ($ Millions)
  • TABLE 23: Rest of the World Market for Microbiome-based Drugs for type 2 Diabetes, by Country/Region, through 2024 ($ Millions)
  • TABLE 24: U.S. Prevalence of Ulcerative Colitis and Crohn's Disease, through 2024 (Thousands)
  • TABLE 25: Microbiome-based Drugs in Development for Ulcerative Colitis and Crohn's Disease
  • TABLE 26: U.S. Market for Microbiome-based Drugs for Ulcerative Colitis and Crohn's Disease, through 2024 ($ Millions)
  • TABLE 27: Rest of the World Market for Microbiome-based Drugs for Ulcerative Colitis and Crohn's Disease, through 2024 ($ Millions)
  • TABLE 28: U.S. Market Shares of Microbiome-based Drugs for Ulcerative Colitis, by Company, 2018-2024 (%)
  • TABLE 29: U.S. Patient Volumes for Microbiome-based Drugs for Ulcerative Colitis, by Company, through 2024 (Thousands)
  • TABLE 30: U.S. Market for Microbiome-based Drugs for Ulcerative Colitis, by Company, through 2024 ($ Millions)
  • TABLE 31: Rest of the World Market for Microbiome-based Drugs for Ulcerative Colitis, by Country/Region, through 2024 ($ Millions)
  • TABLE 32: U.S. Market Shares of Microbiome-based Drugs for Crohn's Disease, by Company, 2018-2024 (%)
  • TABLE 33: U.S. Patient Volumes for Microbiome-based Drugs for Crohn's Disease, by Company, through 2024 (Thousands)
  • TABLE 34: U.S. Market for Microbiome-based Drugs for Crohn's Disease, by Company, through 2024 ($ Millions)
  • TABLE 35: Rest of the World Market for Microbiome-based Drugs for Crohn's Disease, by Country/Region, through 2024 ($ Millions)
  • TABLE 36: U.S. Prevalence of Clostridium Difficle Infection, through 2024 (Thousands)
  • TABLE 37: Microbiome-based Drugs in Development for Clostridium Difficle Infection
  • TABLE 38: U.S. Market Shares of Microbiome-based Drugs for Clostridium Difficile Infection, by Company, 2018-2024 (%)
  • TABLE 39: U.S. Patient Volumes for Microbiome-based Drugs for Clostridium Difficile Infection, by Company, through 2024 (Thousands)
  • TABLE 40: U.S. Market for Microbiome-based Drugs for Clostridium Difficile Infection, by Company, through 2024 ($ Millions)
  • TABLE 41: Rest of the World Market for Microbiome-based Drugs for Clostridium Difficile Infection, by Country/Region, through 2024 ($ Millions)
  • TABLE 42: U.S. Prevalence of Lactose Intolerance, through 2024 (Thousands)
  • TABLE 43: Microbiome-based Drugs in Development for Clostridium Difficle Infection
  • TABLE 44: U.S. Market Shares of Microbiome-based Drugs for Lactose Intolerance, by Company, 2018-2024 (%)
  • TABLE 45: U.S. Patient Volumes for Microbiome-based Drugs for Lactose Intolerance, by Company, through 2024 (Thousands)
  • TABLE 46: U.S. Market for Microbiome-based Drugs for Lactose Intolerance, by Company, through 2024 ($ Millions)
  • TABLE 47: Rest of the World Market for Microbiome-based Drugs for Lactose Intolerance, by Country/Region, through 2024 ($ Millions)
  • TABLE 48: U.S. Prevalence of Dental Caries, through 2024 (Thousands)
  • TABLE 49: Microbiome-based Drugs in Development for Clostridium Difficle Infection
  • TABLE 50: U.S. Market Shares of Microbiome-based Drugs for Dental Caries, by Company, 2018-2024 (%)
  • TABLE 51: U.S. Patient Volumes for Microbiome-based Drugs for Dental Caries, by Company, through 2024 (Thousands)
  • TABLE 52: U.S. Market for Microbiome-based Drugs for Dental Caries, by Company, through 2024 ($ Millions)
  • TABLE 53: Rest of the World Market for Microbiome-based Drugs for Dental Caries, by Country/Region, through 2024 ($ Millions)
  • TABLE 54: U.S. Prevalence of Recurrent Bacterial Vaginosis and Urinary Tract Infection, through 2024 (Thousands)
  • TABLE 55: Microbiome-based Drugs in Development for Recurrent Bacterial Vaginosis and Urinary Tract Infection
  • TABLE 56: U.S. Market Shares of Microbiome-based Drugs for Recurrent Bacterial Vaginosis and Urinary Tract Infection, by Company, 2018-2024 (%)
  • TABLE 57: U.S. Patient Volumes for Microbiome-based Drugs for Recurrent Bacterial Vaginosis and Urinary Tract Infection, by Company, through 2024 (Thousands)
  • TABLE 58: U.S. Market for Microbiome-based Drugs for Recurrent Bacterial Vaginosis and Urinary Tract Infection, by Company, through 2024 ($ Millions)
  • TABLE 59: Rest of the World Market for Microbiome-based Drugs for Recurrent Bacterial Vaginosis and Urinary Tract Infection, by Country/Region, through 2024 ($ Millions)
  • TABLE 60: U.S. Prevalence of Skin Diseases, through 2024 (Thousands)
  • TABLE 61: Microbiome-based Drugs in Development for Skin Diseases
  • TABLE 62: U.S. Market Shares of Microbiome-based Drugs for Skin Diseases, by Company, 2018-2024 (%)
  • TABLE 63: U.S. Patient Volumes for Microbiome-Based Drugs for Skin Diseases, by Company, through 2024 (Thousands)
  • TABLE 64: U.S. Market for Microbiome-based Drugs for Skin Diseases, by Company, through 2024 ($ Millions)
  • TABLE 65: Rest of the World Market for Microbiome-based Drugs for Skin Diseases, by Country/Region, through 2024 ($ Millions)
  • TABLE 66: U.S. Prevalence of Hyperoxaluria, through 2024 (Thousands)
  • TABLE 67: Microbiome-based Drugs in Development for Skin Diseases
  • TABLE 68: U.S. Market Shares of Microbiome-based Drugs for Hyperoxaluria, by Company, 2018-2024 (%)
  • TABLE 69: U.S. Patient Volumes for Microbiome-based Drugs for Hyperoxaluria, by Company, through 2024 (Thousands)
  • TABLE 70: U.S. Market for Microbiome-based Drugs for Hyperoxaluria, by Company, through 2024 ($ Millions)
  • TABLE 71: Rest of the World Market for Microbiome-based Drugs for Hyperoxaluria, by Country/Region, through 2024 ($ Millions)
  • TABLE 72: U.S. Prevalence of Urea Cycle Disorder, through 2024 (Thousands)
  • TABLE 73: Microbiome-based Drugs in Development for Urea Cycle Disorder
  • TABLE 74: U.S. Market Shares of Microbiome-based Drugs for Urea Cycle Disorder, by Company, 2018- 2024 (%)
  • TABLE 75: U.S. Patient Volumes for Microbiome-based Drugs for Urea Cycle Disorder, by Company, through 2024 (Thousands)
  • TABLE 76: U.S. Market for Microbiome-based Drugs for Urea Cycle Disorder, by Company, through 2024 ($ Millions)
  • TABLE 77: U.S. Prevalence of Celiac Disease, through 2024 (Thousands)
  • TABLE 78: Microbiota Associated with Celiac Disease
  • TABLE 79: Microbiome-based Drugs in Development for Celiac Disease
  • TABLE 80: U.S. Market Shares of Microbiome-based Drugs for Celiac Disease, by Company, 2018-2024 (%)
  • TABLE 81: U.S. Patient Volumes for Microbiome-based Drugs for Celiac Disease, by Company, through 2024 (Thousands)
  • TABLE 82: U.S. Market for Microbiome-based Drugs for Celiac Diseases, by Company, through 2024 ($ Millions)
  • TABLE 83: U.S. Prevalence of Phenylketonuria, through 2024 (Thousands)
  • TABLE 84: Microbiome-based Drugs in Development for Phenylketonuria
  • TABLE 85: U.S. Market Shares of Microbiome-based Drugs for Phenylketonuria, by Company, 2018- 2024 (%)
  • TABLE 86: U.S. Patient Volumes for Microbiome-based Drugs for Phenylketonuria, by Company, through 2024 (Thousands)
  • TABLE 87: U.S. Market for Microbiome-based Drugs for Phenylketonuria, by Company, through 2024 ($ Millions)
  • TABLE 88: Rest of the World Market for Microbiome-based Drugs for Celiac Diseases, by Country/Region, through 2024 ($ Millions)
  • TABLE 89: U.S. Prevalence of Non-alcoholic Steatohepatitis, through 2024 (Thousands)
  • TABLE 90: Microbiome-based Drugs in Development for Non-alcoholic Steatohepatitis
  • TABLE 91: U.S. Market Shares of Microbiome-based Drugs for Non-alcoholic Steatohepatitis, by Company, 2018-2024 (%)
  • TABLE 92: U.S. Patient Volumes for Microbiome-based Drugs for Non-alcoholic Steatohepatitis, by Company, through 2024 (Thousands)
  • TABLE 93: U.S. Market for Microbiome-based Drugs for Non-alcoholic Steatohepatitis, by Company, through 2024 ($ Millions)
  • TABLE 94: Rest of the World Market for Microbiome-based Drugs for Non-alcoholic Steatohepatitis, by Country/Region, through 2024 ($ Millions)
  • TABLE 95: U.S. Prevalence of Hepatic Encephalopathy, through 2024 (Thousands)
  • TABLE 96: Microbiome-based Drugs in Development for Hepatic Encephalopathy
  • TABLE 97: U.S. Market Shares of Microbiome-based Drugs for Hepatic Encephalopathy, by Company, 2018-2024 (%)
  • TABLE 98: U.S. Patient Volumes for Microbiome-based Drugs for Hepatic Encephalopathy, by Company, through 2024 (Thousands)
  • TABLE 99: U.S. Market for Microbiome-based Drugs for Hepatic Encephalopathy, by Company, through 2024 ($ Millions)
  • TABLE 100: Rest of the World Market for Microbiome-based Drugs for Hepatic Encephalopathy, by Country/Region, through 2024 ($ Millions)
  • TABLE 101: Comparison of Microbiome Sequencing Technologies
  • TABLE 102: U.S. Market for Microbiome-based Diagnostics, by Disease Segment, through 2024 ($ Millions)
  • TABLE 103: Rest of the World Market for Microbiome-based Diagnostics, by Country/Region, through 2024 ($ Millions)
  • TABLE 104: U.S. Market Shares of Microbiome-based Diagnostics for Ulcerative Colitis and Crohn's Disease, 2018-2024 (%)
  • TABLE 105: U.S. Assay Volumes for Microbiome-based Diagnostics for Ulcerative Colitis and Crohn's Disease, through 2024 (Thousands)
  • TABLE 106: U.S. Market for Microbiome-based Diagnostics for Ulcerative Colitis and Crohn's Disease, through 2024 ($ Millions)
  • TABLE 107: U.S. Prevalence of Microbiome-based Diagnostics for Colorectal Cancer, through 2024 (Thousands)
  • TABLE 108: U.S. Market Shares of Microbiome-based Diagnostics for Colorectal Cancer, by Company, 2018-2024 (%)
  • TABLE 109: U.S. Assay Volumes for Microbiome-based Diagnostics for Colorectal Cancer, through 2024 (Thousands)
  • TABLE 110: U.S. Market for Microbiome-based Diagnostics for Colorectal Cancer, through 2024 ($ Millions)
  • TABLE 111: U.S. Prevalence of Microbiome-based Diagnostics for Women's Health, through 2024 (Thousands)
  • TABLE 112: U.S. Market Shares of Microbiome-based Diagnostics for Women's Health, by Company, 2018-2024 (%)
  • TABLE 113: U.S. Assay Volumes for Microbiome-based Diagnostics for Women's Health, through 2024 (Thousands)
  • TABLE 114: U.S. Market for Microbiome-based Diagnostics for Women's Health, through 2024 ($ Millions)
  • TABLE 115: U.S. Market Shares of Microbiome-based Diagnostics for Dental Caries, by Company, 2018- 2024 (%)
  • TABLE 116: U.S. Assay Volumes for Microbiome-based Diagnostics for Dental Caries, through 2024 (Thousands)
  • TABLE 117: U.S. Market for Microbiome-based Diagnostics for Dental Caries, by Company through 2024 ($ Millions)
  • TABLE 118: U.S. Patents and Patent Applications on Microbiome-based Drugs for C. Difficle Infection
  • TABLE 119: U.S. Patents and Patent Applications on Microbiome-based Drugs for Irritable Bowel Syndrome
  • TABLE 120: U.S. Patents and Patent Applications on Microbiome-based Drugs for Diabetes and Obesity
  • TABLE 121: U.S. Patents and Patent Applications on Microbiome-based Drugs for Cancer
  • TABLE 122: U.S. Patents and Patent Applications on Microbiome-based Drugs for Lactose Intolerance
  • TABLE 123: U.S. Patents and Patent Applications on Microbiome-based Drugs for Hyperxaluria
  • TABLE 124: U.S. Patents and Patent Applications on Microbiome-based Drugs for Recurrent Bacterial Vaginosis and Urniary Tract Infection
  • TABLE 125: U.S. Patents and Patent Applications on Microbiome-Based Drugs for Dental Caries
  • TABLE 126: U.S. Patents and Patent Applications on Microbiome-based Drugs for Urea Cycle Disorders
  • TABLE 127: Venture Capital Investments in Microbiome Start-Ups ($ Millions)
  • TABLE 128: Initial Public Offerings by Microbiome-Based Companies ($ Millions)
  • TABLE 129: Industry collaborations in Microbiome-based Companies ($ Millions)
  • TABLE 130: 4D Pharma Pipeline
  • TABLE 131: Avidbiotics Pipeline
  • TABLE 132: AObiome Pipeline
  • TABLE 133: C3 Jian Pipeline
  • TABLE 134: Caelus Pipeline
  • TABLE 135: Da Volterra Pipeline
  • TABLE 136: Enterome Pipeline
  • TABLE 137: Microbiome Therapeutics Pipeline
  • TABLE 138: Osel Pipeline
  • TABLE 139: Oxthera Pipeline
  • TABLE 140: Oxthera Pipeline
  • TABLE 141: Rebiotix Pipeline
  • TABLE 142: Second Genome Pipeline
  • TABLE 143: Seres Therapeutics Pipeline
  • TABLE 144: Synlogic Pipeline
  • TABLE 145: Synthetic Biologics Pipeline
  • TABLE 146: Vedanta Biosciences Pipeline
  • TABLE 147: ViThera Pharmaceuticals Pipeline

List of Figures

  • FIGURE 1: Summary Figure A: Global Market for Human Microbiome Based Drugs and Diagnostics, 2018-2024 ($ Millions)
  • FIGURE 2: Summary Figure B: Global Market for Human Microbiome Based Drugs by Region, 2018-2024 ($ Millions)
  • FIGURE 3: Summary Figure C: Global Market for Human Microbiome Based Diagnostics by Region, 2018-2024 ($ Millions)
  • FIGURE 4: Human Microbiome Based Drugs, Pipeline Projects, 2016 (Number of Clinical/Preclinical Projects)
  • FIGURE 5: Microbes Involved in Healthy Facial Skin (Percent Microbes)
  • FIGURE 6: Number of Patents Granted for Worldwide Microbiome-based Drugs, 2002-2016
Back to Top